MedTrace Logo

Current Status of BTKi Treatment for CLL/SLL in China

NCT06508684 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-07-18

No results posted yet for this study

Summary

BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.

Conditions

  • CLL/SLL

Interventions

DRUG

BTK inhibitor

BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-13
Primary Completion
2025-02-12
Completion
2025-07-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06508684 on ClinicalTrials.gov